Industries de la santé
13 Avril 2011
Pluristem Announces Encouraging Six-Month Follow-up Results of its Phase I Critical Limb Ischemia Clinical Trials |HAIFA, ISRAEL, April 13, 2011 -- Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR;), today announced that following completion of three and six month clinical follow-up, data from its two open-label, dose-escalation, Phase I clinical trials conducted in the US and...